Centre advises rapid testing for entire populations in Covid-19 hotspots

Maitri Porecha New Delhi | Updated on April 03, 2020 Published on April 03, 2020

But shortage of kits amid regulatory confusion may prove a hurdle for States

As Covid-19 cases rise sharply across the country, the Centre has said that entire populations in hotspot areas can be tested using rapid antibody tests. These are tests which can be run on blood, plasma or serum samples, are used to ascertain in less than 30 minutes if a person, even if asymptomatic, is Covid-19 positive.

The test usually comes positive if the person on whom it is being run has been infected with the SARS-COV2 virus, which leads to Covid-19 in 7-10 days. The test remains positive for several weeks after the infection, Indian Council Medical Research (ICMR) officials have stated.

Top hotspots

The Centre has identified 25 districts with high case loads, including Mumbai, Kasargod, Hyderabad, Kannur, Pune, Gautam Buddh Nagar (Uttar Pradesh) and Bengaluru, which are the top seven cities, with more than 30 cases each. As on March 31, Mumbai had 142 cases while Kasargod had 107 cases, an internal report on hotspots compiled by the Ministry of Health and Family Welfare stated. In addition to these, three districts each in Gujarat and Kerala and two in Punjab are seen as emerging hotspots.

In its interim advisory of April 2, the ICMR said those who are antibody positive in rapid testing should be further tested and confirmed through the real time polymerase chain reaction (RT-PCR) test, which is conducted by collecting nasal and throat swabs. Those who are negative in the rapid test should still be quarantined at home, because they are in Covid-19 hotspots anyway and may be susceptible to contracting the infection. “Negative test does not rule out Covid-19 infection,” the ICMR advisory said.

Looking for guidance

Even as the ICMR released the interim advisory and an emergency meeting of the National Task Force to finalise the recommendations was held on Thursday, distributors of antibody kits complained that while States were willing to buy the kits, they were waiting to receive guidance from the ICMR on how to proceed.

An Indian distributor of a Chinese company supplying these kits that have already been approved by European regulator CE-IVD, on basis of anonymity, told Businessline: “We have orders now from at least two States who need 2.5 lakh kits in total, but have stated that first we will have to run those kits for validation through ICMR.”

For instance, Bihar, Jharkhand and Assam have been demanding that even CE-IVD kits be first sent to the ICMR for validation.

ICMR’s clarification

However, the ICMR, in its advisory, clarified that CE-IVD-approved kits can be used directly after due approval from the Drug Controller General of India (DCGI) and intimation to the ICMR. The DCGI has not yet made public the list of diagnostic companies and the companies that supply test kits — be it domestic or international — to whom it has granted approval for starting supply in India.

On March 28, the ICMR had released a list of 12 CE-IVD-approved antibody-based rapid kits manufactured in the US, China, Singapore, Poland and India. It also named a Chinese company called Wondfo, whose technology is not CE-IVD-approved but has been validated by the ICMR.

As far as the lab-based RT-PCR tests go, the ICMR, on Thursday, said that it had completed evaluating 20 non-US-FDA or CE-IVD-approved technologies. It also approved kits from five companies — Kilpest (38 Blackbio), SD Biosensor, Seegene, Mylab and Altona Diagnostics. Labs, be they public or private, can only procure kits from these companies or any other kits which are approved by US/European regulators after due approval from the DCGI and intimation to ICMR, it said.

Published on April 03, 2020

A letter from the Editor

Dear Readers,

The coronavirus crisis has changed the world completely in the last few months. All of us have been locked into our homes, economic activity has come to a near standstill. Everyone has been impacted.

Including your favourite business and financial newspaper. Our printing and distribution chains have been severely disrupted across the country, leaving readers without access to newspapers. Newspaper delivery agents have also been unable to service their customers because of multiple restrictions.

In these difficult times, we, at BusinessLine have been working continuously every day so that you are informed about all the developments – whether on the pandemic, on policy responses, or the impact on the world of business and finance. Our team has been working round the clock to keep track of developments so that you – the reader – gets accurate information and actionable insights so that you can protect your jobs, businesses, finances and investments.

We are trying our best to ensure the newspaper reaches your hands every day. We have also ensured that even if your paper is not delivered, you can access BusinessLine in the e-paper format – just as it appears in print. Our website and apps too, are updated every minute, so that you can access the information you want anywhere, anytime.

But all this comes at a heavy cost. As you are aware, the lockdowns have wiped out almost all our entire revenue stream. Sustaining our quality journalism has become extremely challenging. That we have managed so far is thanks to your support. I thank all our subscribers – print and digital – for your support.

I appeal to all or readers to help us navigate these challenging times and help sustain one of the truly independent and credible voices in the world of Indian journalism. Doing so is easy. You can help us enormously simply by subscribing to our digital or e-paper editions. We offer several affordable subscription plans for our website, which includes Portfolio, our investment advisory section that offers rich investment advice from our highly qualified, in-house Research Bureau, the only such team in the Indian newspaper industry.

A little help from you can make a huge difference to the cause of quality journalism!

Support Quality Journalism
This article is closed for comments.
Please Email the Editor
You have read 1 out of 3 free articles for this week. For full access, please subscribe and get unlimited access to all sections.